RWE in Pharma: 5 minutes with…Riad Dirani

In this ‘RWE in Pharma’ interview series, we are putting various pharma experts in the spotlight and asking them to share their insight on how their industry has traditionally employed real-world evidence (RWE), how they envision this changing over the next few years and what their predictions of the impacts of the highly anticipated US FDA RWE Framework may be. Our expert for this instalment is Riad Dirani, Vice President of Global Health Economics and Outcomes Research/Epidemiology at Teva Pharmaceuticals (NJ, USA). Please could you introduce yourself, your organization(s) and tell us more about your role?  I serve as the Vice President...